💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

California judge orders next Monsanto weed-killer cancer trial for March

Published 11/15/2018, 06:43 PM
© Reuters. FILE PHOTO: A woman uses a Monsanto's Roundup weedkiller spray without glyphosate in a garden in Ercuis near Paris
BAYGN
-
MON
-

By Tina Bellon

(Reuters) - A California judge on Thursday granted an expedited trial in the case of a California couple suffering from cancer who sued Bayer AG's (DE:BAYGn) Monsanto (NYSE:MON) unit, alleging the company's glyphosate-containing weed killer Roundup caused their disease.

The order by Superior Court Judge Ioana Petrou in Oakland, California, comes on the heels of a $289 million verdict in the first glyphosate trial in San Francisco, in which a jury found Monsanto liable for causing a school groundskeeper's cancer.

Damages were later reduced to $78 million, and Bayer, which denies the allegations, said it would appeal the decision.

Its share price, however, has dropped nearly 30 percent since the Aug. 10 jury verdict and the company faces some 9,300 U.S. glyphosate lawsuits.

Petrou's ruling clears the way for the second California jury trial over glyphosate, the world's most widely used weed killer. The trial of California residents Alva and Alberta Pilliod is scheduled to begin on March 18, 2019, according to a court filing.

"While we have great sympathy for the plaintiffs, we are confident that our glyphosate-based herbicides were not the cause of their injuries and we will vigorously defend them at trial," the company said in a statement.

Glyphosate jury trials will ramp up next year. The company is scheduled to face jurors in a Missouri state court in St. Louis, where the first trial was set to begin in early February. That date, however, was vacated by a judge, Bayer said, and the trial is likely to be postponed to later in 2019.

A trial in San Francisco federal court, where federal Roundup lawsuits are consolidated, is scheduled to begin at the end of February.

Bayer, which acquired Monsanto earlier this year for $63 billion, says its glyphosate-based products do not cause cancer, pointing to decades of scientific studies and regulatory approvals that have shown the chemical to be safe for human use.

The U.S. Environmental Protection Agency in September 2017 concluded a decades-long assessment of glyphosate risks and found the chemical not likely carcinogenic to humans. But the World Health Organization's cancer arm in 2015 classified glyphosate as "probably carcinogenic to humans."

The Pilliods, who are in their 70s, allege their regular use of Roundup between 1975 and 2011 caused them to develop non-Hodgkin lymphoma, a cancer of the lymph system.

© Reuters. FILE PHOTO: A woman uses a Monsanto's Roundup weedkiller spray without glyphosate in a garden in Ercuis near Paris

The couple filed their lawsuit in June 2017, after being diagnosed with the cancer in 2011 and 2015 respectively. Their lawyers earlier this year asked for an expedited trial, citing the couple's risk of a relapse and their short life expectancy.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.